Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors.
Dung T. Le
No relevant relationships to disclose
Nilofer Saba Azad
No relevant relationships to disclose
Dan Laheru
No relevant relationships to disclose
Ilene S. Browner
No relevant relationships to disclose
Hao Wang
No relevant relationships to disclose
Jennifer N. Uram
No relevant relationships to disclose
Holly Kemberling
No relevant relationships to disclose
Lei Zheng
No relevant relationships to disclose
Robert Iannone
Employment or Leadership Position - Merck
Evan Friedman
Employment or Leadership Position - Merck
Amy Meister
Employment or Leadership Position - Merck
Ross C. Donehower
No relevant relationships to disclose
Ana De Jesus-Acosta
No relevant relationships to disclose
Luis A. Diaz
No relevant relationships to disclose